论文部分内容阅读
北京中药总厂经两年多的努力,研制成以人参、牛黄、蟾蜍等名贵中药为主要原料的微丸中成药“营心丹”(原名:心乐宁)。经北京友谊医院、北京医学院第一、第三附属医院、同仁医院、积水潭医院等20个医疗单位,对503例冠心病心绞痛中、重型患者进行临床观察,其中中型患者有效率达92.6%,重型患者有效率达79.5%,总有效率为88.9%。没有明显副作用。经北京市有关大专院校和科研院所的药理、毒理学实验证明,“营心丹”具有加强心肌收缩力,减慢心率,提高心脏抗缺氧效应,抑制血小板聚集,增强尿激酶活性,消除血栓形成等作用。1983年L2月1日经北京市卫生局,北京市医药总公司邀请在京有关专家鉴定,认为该药有“养心通脉,镇静安神”功能。主治由于心气、心阳虚亏所引起的胸闷、心悸,心痛属于心肌缺血所致冠心病心绞痛等。会议希望尽快正式投入生产,以满足临床应用需要。
After more than two years of hard work, Beijing Traditional Chinese Medicine Factory developed a pelleted proprietary Chinese medicine called “Xinxindan” (original name: Xinlein) that uses ginseng, bezoar, wolfberry and other precious Chinese medicines as its main raw materials. Through 20 medical units such as Beijing Friendship Hospital, Beijing First Affiliated Hospital, Tongren Hospital, and Jishuitan Hospital, 503 patients with coronary heart disease with moderate or severe angina have been observed clinically, of which medium-sized patients have an effective rate of 92.6%. The effective rate of heavy patients was 79.5%, and the total effective rate was 88.9%. There are no obvious side effects. According to pharmacological and toxicological experiments conducted by relevant universities and research institutes in Beijing, “Xinxindan” has enhanced myocardial contractility, slowed heart rate, increased cardiac anti-hypoxia, inhibited platelet aggregation, and enhanced urokinase Activity, eliminate thrombosis and other effects. On February 1, 1983, Beijing Municipal Health Bureau and Beijing Pharmaceutical Corporation invited experts from Beijing to identify that the drug had a “Yang Xin Tongmai, Calm, Calm, and Tranquilization” function. Indications due to heart qi, heart Yang deficiency caused by chest tightness, heart palpitations, heartache is due to myocardial ischemia caused by coronary heart disease angina. The meeting hopes to formally put into production as soon as possible to meet the needs of clinical applications.